gc2126a

GC2126A is a **small molecule drug** in preclinical development by GC Biopharma Corp., designed for the treatment of gangliosidoses, a class of lysosomal storage diseases that cause severe neurodegenerative symptoms. GC2126A is being evaluated for indications within nervous system diseases, congenital disorders, and endocrinology and metabolic diseases. Preclinical results presented by GC Biopharma indicate significant reduction of substrate (likely GM1 ganglioside) in relevant animal models. GC2126A does not have published detailed mechanistic data, but it is classified as a treatment for lysosomal storage disease, implying its mechanism is expected to modulate the accumulation or clearance of pathogenic metabolites associated with gangliosidoses[1][7][11][13].